Setareh Seyedkazemi - 06 Jan 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Development Officer
Signature: Setareh Seyedkazemi, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol: ADVM
Transactions as of: 06 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 10 Jan 2022, 16:04:47 UTC
Next filing: 24 May 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+425,000		$0.000000	425,000	06 Jan 2022	Common Stock	425,000	$1.73	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of January 6, 2022 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Content

Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of January 6, 2022 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.